OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd has launched an entitlement offer to raise around $5.65 million, with the prospectus dispatched to shareholders and applications open until April 24, 2024. The company is advancing in commercializing its OncoSil™ brachytherapy device for treating pancreatic cancer, which is approved for sale in over 30 countries and has begun treatments in select European and Middle Eastern countries.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
